Photobiomodulation Therapy and Cell Therapy Improved Parkinson’s Diseases by Neuro-regeneration and Tremor Inhibition Photobiomodulation therapy and cell therapy in Parkinson diseases
Journal of Lasers in Medical Sciences,
Vol. 13 (2022),
10 January 2022
,
Page e28
Abstract
Introduction: Parkinson's disease is a progressive and severe neurodegenerative disorder of the central nervous system. The most prominent features of this disease are cell reduction in Substantia nigra and accumulation of α-Synuclein, especially in the brainstem, spinal cord, and cortical areas. In addition to drug-based treatment, other therapies such as surgery, cell therapy, laser therapy can be mentioned. In this study, articles on cell therapy and laser therapy for Parkinson's disease have been collected to evaluate the improvement of motor function, cell differentiation, and dopaminergic cell proliferation. Method: Articles were collected from four electronic databases PubMed, Scopus, Google Scholar Web of Science from 2010 to 2022 and electronically to study the effects of stem cell therapy and laser therapy on Parkinson's disease through the keywords "photobiomodulation", "low-level light therapy", "Low-level laser therapy", "near-infrared light", "Parkinson's disease", "Parkinsonism" and "stem cell therapy" were searched. About 80 related articles were included in the study. Result: The results of studies show that cell therapy and laser therapy are each useful in the treatment of Parkinson's disease and despite their limitations can be useful in improving Parkinson's disease. Conclusion: Concomitant use of cell therapy and Photobiomodulation therapy can improve the symptoms of Parkinson's.
- Parkinson's disease, near-infrared light, laser therapy, stem cell therapy
How to Cite
References
2. Ang S-L. Transcriptional control of midbrain dopaminergic neuron development. 2006.
3. Spatola M, Wider C. Genetics of Parkinson's disease: the yield. Parkinsonism & related disorders. 2014;20:S35-S8.
4. Veldman B, Wijn A, Knoers N, Praamstra P, Horstink M. Genetic and environmental risk factors in Parkinson’s disease. Clinical neurology and neurosurgery. 1998;100(1):15-26.
5. Chen D, Fu W, Zhuang W, Lv C, Li F, Wang X. Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson's disease. Journal of neuroscience research. 2017;95(3):907-17.
6. Magotani H, Kikuchi T, Ikeda M, Hiramatsu S, Yoshida K, Amano N, et al. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson’s disease. Nature communications. 2020;11(1):1-14.
7. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta‐analysis. Movement disorders. 2014;29(13):1583-90.
8. Braak H, Del Tredici K, Rüb U, De Vos RA, Steur ENJ, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of aging. 2003;24(2):197-211.
9. Ubeda-Banon I, Saiz-Sanchez D, de la Rosa-Prieto C, Argandona-Palacios L, Garcia-Munozguren S, Martinez-Marcos A. α-Synucleinopathy in the human olfactory system in Parkinson’s disease: involvement of calcium-binding protein-and substance P-positive cells. Acta neuropathologica. 2010;119(6):723-35.
10. Barrett KE, Boitano S, Barman SM, Brooks HL. Ganong’s review of medical physiology twenty. 2010.
11. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Archives of neurology. 2010;67(7):798-801.
12. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Movement disorders: official journal of the Movement Disorder Society. 2001;16(4):622-30.
13. Lin T-K, Liou C-W, Chen S-D, Chuang Y-C, Tiao M-M, Wang P-W, et al. Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson’s disease. Chang Gung Med J. 2009;32(6):589-99.
14. Berry C, La Vecchia C, Nicotera P. Paraquat and Parkinson's disease. Cell Death & Differentiation. 2010;17(7):1115-25.
15. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nature Reviews Neuroscience. 2001;2(7):492-501.
16. Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nature Reviews Neuroscience. 2002;3(12):932-42.
17. Hampe C, Ardila-Osorio H, Fournier M, Brice A, Corti O. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin–protein ligase with monoubiquitylation capacity. Human molecular genetics. 2006;15(13):2059-75.
18. Levin L, Srour S, Gartner J, Kapitansky O, Qutob N, Dror S, et al. Parkin somatic mutations link melanoma and Parkinson's disease. Journal of Genetics and Genomics. 2016;43(6):369-79.
19. Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang J-W, et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proceedings of the National Academy of Sciences. 2006;103(28):10793-8.
20. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron. 2015;85(2):257-73.
21. Foltynie T, Sawcer S, Brayne C, Barker R. The genetic basis of Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry. 2002;73(4):363-70.
22. Ragland M, Hutter C, Zabetian C, Edwards K. Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis. American journal of epidemiology. 2009;170(11):1344-57.
23. Gandhi S, Muqit M, Stanyer L, Healy D, Abou-Sleiman P, Hargreaves I, et al. PINK1 protein in normal human brain and Parkinson's disease. Brain. 2006;129(7):1720-31.
24. Lockhart P, Lincoln S, Hulihan M, Kachergus J, Wilkes K, Bisceglio G, et al. DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. Journal of medical genetics. 2004;41(3):e22-e.
25. Ferreira M, Massano J. An updated review of Parkinson's disease genetics and clinicopathological correlations. Acta Neurologica Scandinavica. 2017;135(3):273-84.
26. Biskup S, West AB. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2009;1792(7):625-33.
27. Simola N, Pinna A, Fenu S. Pharmacological therapy of Parkinson's disease: current options and new avenues. Recent Patents on CNS Drug Discovery (Discontinued). 2010;5(3):221-38.
28. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays. 2002;24(4):308-18.
29. Vazifehkhah S, Karimzadeh F. Parkinson Disease: from Pathophysiology to the Animal Models. The Neuroscience Journal of Shefaye Khatam. 2016;4(3):91-102.
30. Beitz JM. Parkinson’s disease: a review. Front Biosci (Schol Ed). 2014;6(6):65-74.
31. Bigini P, Veglianese P, Andriolo G, Cova L, Grignaschi G, Caron I, et al. Intracerebroventricular administration of human umbilical cord blood cells delays disease progression in two murine models of motor neuron degeneration. Rejuvenation research. 2011;14(6):623-39.
32. Pereira MC, Secco M, Suzuki DE, Janjoppi L, Rodini CO, Torres LB, et al. Contamination of mesenchymal stem-cells with fibroblasts accelerates neurodegeneration in an experimental model of Parkinson’s disease. Stem cell reviews and reports. 2011;7(4):1006-17.
33. Buzhor E, Leshansky L, Blumenthal J, Barash H, Warshawsky D, Mazor Y, et al. Cell-based therapy approaches: the hope for incurable diseases. Regenerative medicine. 2014;9(5):649-72.
34. Fu M-H, Li C-L, Lin H-L, Chen P-C, Calkins MJ, Chang Y-F, et al. Stem cell transplantation therapy in Parkinson’s disease. Springerplus. 2015;4(1):1-8.
35. Tønnesen J, Parish CL, Sørensen AT, Andersson A, Lundberg C, Deisseroth K, et al. Functional integration of grafted neural stem cell-derived dopaminergic neurons monitored by optogenetics in an in vitro Parkinson model. PloS one. 2011;6(3):e17560.
36. Nooraei MS, Noori-Zadeh A, Darabi S, Rajaei F, Golmohammadi Z, Abbaszadeh HA. Low level of autophagy-related gene 10 (ATG10) expression in the 6-hydroxydopamine rat model of Parkinson’s disease. Iranian biomedical journal. 2018 Jan;22(1):15.
37. Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regenerative medicine. 2010;5(6):933-46.
38. Abbaszadeh HA, Tiraihi T, Delshad A, Saghedizadeh M, Taheri T, Kazemi H, Hassoun HK. Differentiation of neurosphere-derived rat neural stem cells into oligodendrocyte-like cells by repressing PDGF-α and Olig2 with triiodothyronine. Tissue and cell. 2014 Dec 1;46(6):462-9.
39. Morandi F, Raffaghello L, Bianchi G, Meloni F, Salis A, Millo E, et al. Immunogenicity of human mesenchymal stem cells in HLA‐class I‐restricted T‐cell responses against viral or tumor‐associated antigens. Stem cells. 2008;26(5):1275-87.
40. Shetty P, Thakur AM, Viswanathan C. Dopaminergic cells, derived from a high efficiency differentiation protocol from umbilical cord derived mesenchymal stem cells, alleviate symptoms in a Parkinson's disease rodent model. Cell biology international. 2013;37(2):167-80.
41. Jalali MS, Sarkaki A, Farbood Y, Azandeh SS, Mansouri E, Dehcheshmeh MG, et al. Neuroprotective effects of Wharton’s jelly-derived mesenchymal stem cells on motor deficits due to Parkinson’s disease. Iranian Journal of Basic Medical Sciences. 2021;24(9):1173.
42. Tse W, Bunting KD. The expanding tool kit for hematopoietic stem cell research. Hematopoietic Stem Cell Protocols. 2008:3-18.
43. Xiong N, Zhang Z, Huang J, Chen C, Jia M, Xiong J, et al. VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson’s disease. Gene therapy. 2011;18(4):394-402.
44. Jinfeng L, Yunliang W, Xinshan L, Yutong W, Shanshan W, Peng X, et al. Therapeutic effects of CUR-activated human umbilical cord mesenchymal stem cells on 1-methyl-4-phenylpyridine-induced Parkinson’s disease cell model. BioMed research international. 2016;2016.
45. Abbaszadeh HA, Tiraihi T, Delshad AR, Zadeh MS, Taheri T. Bone marrow stromal cell transdifferentiation into oligodendrocyte-like cells using triiodothyronine as a inducer with expression of platelet-derived growth factor α as a maturity marker. Iranian biomedical journal. 2013 Apr;17(2):62.
46. Bagheri-Mohammadi S, Alani B, Karimian M, Moradian-Tehrani R, Noureddini M. Intranasal administration of endometrial mesenchymal stem cells as a suitable approach for Parkinson’s disease therapy. Molecular biology reports. 2019;46(4):4293-302.
47. Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T. Bladder and bowel dysfunction in Parkinson’s disease. Journal of neural transmission. 2008;115(3):443-60.
48. Campeau L, Soler R, Andersson K-E. Bladder dysfunction and parkinsonism: current pathophysiological understanding and management strategies. Current urology reports. 2011;12(6):396-403.
49. Soler R, Füllhase C, Hanson A, Campeau L, Santos C, Andersson K-E. Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. The Journal of urology. 2012;187(4):1491-7.
50. Yin X, Xu H, Jiang Y, Deng W, Wu Z, Xiang H, et al. The effect of lentivirus-mediated PSPN genetic engineering bone marrow mesenchymal stem cells on Parkinson’s disease rat model. PLoS One. 2014;9(8):e105118.
51. Darabi SH, Tiraihi T, Noori-Zadeh A, Rajaei F, Darabi L, Abbaszadeh H. Creatine and retinoic acid effects on the induction of autophagy and differentiation of adipose tissue-derived stem cells into GABAergic-like neurons. Journal of Babol university of medical sciences. 2017 Aug 10;19(8):41-9.
52. Zhang L, Liu L, Thompson R, Chan C. CREB modulates calcium signaling in cAMP-induced bone marrow stromal cells (BMSCs). Cell calcium. 2014;56(4):257-68.
53. Wang F, Yasuhara T, Shingo T, Kameda M, Tajiri N, Yuan WJ, et al. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1α. BMC neuroscience. 2010;11(1):1-9.
54. Schiess M, Suescun J, Doursout MF, Adams C, Green C, Saltarrelli JG, et al. Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease. Movement Disorders. 2021;36(8):1825-34.
55. Huang T, He D, Kleiner G, Kuluz JT. Neuron-like differentiation of adipose-derived stem cells from infant piglets in vitro. The journal of spinal cord medicine. 2007;30(sup1):S35-S40.
56. Gao S, Guo X, Zhao S, Jin Y, Zhou F, Yuan P, et al. Differentiation of human adipose-derived stem cells into neuron/motoneuron-like cells for cell replacement therapy of spinal cord injury. Cell death & disease. 2019;10(8):1-15.
57. Ahmed H, Salem A, Atta H, Ghazy M, Aglan H. RETRACTED: Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson’s disease in rat model? Human & experimental toxicology. 2014;33(12):1217-31.
58. Shim JH, Yoon SH, Kim K-H, Han JY, Ha J-Y, Hyun DH, et al. The antioxidant Trolox helps recovery from the familial Parkinson's disease-specific mitochondrial deficits caused by PINK1-and DJ-1-deficiency in dopaminergic neuronal cells. Mitochondrion. 2011;11(5):707-15.
59. Choi HS, Kim HJ, Oh J-H, Park H-G, Ra JC, Chang K-A, et al. Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson's disease. Neurobiology of Aging. 2015;36(10):2885-92.
60. Niu X, Chen J, Gao J. Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances. Asian journal of pharmaceutical sciences. 2019;14(5):480-96.
61. Stephen ZR, Kievit FM, Zhang M. Magnetite nanoparticles for medical MR imaging. Materials Today. 2011;14(7-8):330-8.
62. Danielyan L, Schäfer R, von Ameln-Mayerhofer A, Bernhard F, Verleysdonk S, Buadze M, et al. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation research. 2011;14(1):3-16.
63. Teixeira FG, Carvalho MM, Panchalingam KM, Rodrigues AJ, Mendes-Pinheiro B, Anjo S, et al. Impact of the secretome of human mesenchymal stem cells on brain structure and animal behavior in a rat model of Parkinson's disease. Stem cells translational medicine. 2017;6(2):634-46.
64. Teixeira FG, Vilaça-Faria H, Domingues AV, Campos J, Salgado AJ. Preclinical comparison of stem cells secretome and levodopa application in a 6-hydroxydopamine rat model of Parkinson’s disease. Cells. 2020;9(2):315.
65. Peyvandi AA, Roozbahany NA, Peyvandi H, Abbaszadeh HA, Majdinasab N, Faridan M, Niknazar S. Critical role of SDF-1/CXCR4 signaling pathway in stem cell homing in the deafened rat cochlea after acoustic trauma. Neural regeneration research. 2018 Jan;13(1):154.
66. Cova L, Armentero M-T, Zennaro E, Calzarossa C, Bossolasco P, Busca G, et al. Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. Brain research. 2010;1311:12-27.
67. Simorgh S, Bagher Z, Farhadi M, Kamrava SK, Boroujeni ME, Namjoo Z, et al. Magnetic Targeting of Human Olfactory Mucosa Stem Cells Following Intranasal Administration: a Novel Approach to Parkinson’s Disease Treatment. Molecular Neurobiology. 2021;58(8):3835-47.
68. Farhadi M, Boroujeni ME, Kamrava SK, Bagher Z, Tehrani AM, Aghajanpour F, et al. Implantation of human olfactory ecto-mesenchymal stem cells restores locomotion in a rat model of Parkinson's disease. Journal of Chemical Neuroanatomy. 2021;114:101961.
69. Cova L, Bossolasco P, Armentero M-T, Diana V, Zennaro E, Mellone M, et al. Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinson’s disease. Apoptosis. 2012;17(3):289-304.
70. Kikuchi T, Morizane A, Magotani H, Onoe H, Hayashi T, Mizuma H, et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model. Nature. 2017;548(7669):592-6.
71. Cooper O, Hargus G, Deleidi M, Blak A, Osborn T, Marlow E, et al. Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Molecular and Cellular Neuroscience. 2010;45(3):258-66.
72. Soderstrom K, Meredith G, Freeman T, McGuire S, Collier T, Sortwell C, et al. The synaptic impact of the host immune response in a parkinsonian allograft rat model: influence on graft-derived aberrant behaviors. Neurobiology of disease. 2008;32(2):229-42.
73. Kirkeby A, Grealish S, Wolf DA, Nelander J, Wood J, Lundblad M, et al. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell reports. 2012;1(6):703-14.
74. Xi J, Liu Y, Liu H, Chen H, Emborg ME, Zhang SC. Specification of midbrain dopamine neurons from primate pluripotent stem cells. Stem cells. 2012;30(8):1655-63.
75. Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, et al. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC‐, hiPSC‐, and non‐human primate iPSC‐derived dopaminergic neurons. Stem cells. 2013;31(8):1548-62.
76. Ono Y, Nakatani T, Sakamoto Y, Mizuhara E, Minaki Y, Kumai M, et al. Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells. 2007.
77. Doi D, Samata B, Katsukawa M, Kikuchi T, Morizane A, Ono Y, et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem cell reports. 2014;2(3):337-50.
78. Samata B, Nishimura K, Kikuchi T, Watanabe A, Sakamoto Y, Kakuta J, et al. Purification of functional human ES and iPSC-derived midbrain dopaminergic progenitors using LRTM1. Nature communications. 2016;7(1):1-11.
79. Gonzalez R, Garitaonandia I, Poustovoitov M, Abramihina T, McEntire C, Culp B, et al. Neural stem cells derived from human parthenogenetic stem cells engraft and promote recovery in a nonhuman primate model of Parkinson's disease. Cell transplantation. 2016;25(11):1945-66.
80. Quirk BJ, DeSmet KD, Henry M, Buchmann E, Wong-Riley M, Eells JT, et al. Therapeutic effect of near infrared (NIR) light on Parkinson’s disease models. Front Biosci (Elite Ed). 2012;4:818-23.
81. Oueslati A, Lovisa B, Perrin J, Wagnieres G, van den Bergh H, Tardy Y, et al. Photobiomodulation suppresses alpha-synuclein-induced toxicity in an AAV-based rat genetic model of Parkinson’s disease. PloS one. 2015;10(10):e0140880.
82. Mohsenifar Z, Fridoni M, Ghatrehsamani M, Abdollahifar MA, Abbaszadeh H, Mostafavinia A, Fallahnezhad S, Asghari M, Bayat S, Bayat M. Evaluation of the effects of pulsed wave LLLT on tibial diaphysis in two rat models of experimental osteoporosis, as examined by stereological and real-time PCR gene expression analyses. Lasers in medical science. 2016 May;31(4):721-32.
83. El Massri N, Johnstone DM, Peoples CL, Moro C, Reinhart F, Torres N, et al. The effect of different doses of near infrared light on dopaminergic cell survival and gliosis in MPTP-treated mice. International Journal of Neuroscience. 2016;126(1):76-87.
84. El Massri N, Lemgruber AP, Rowe IJ, Moro C, Torres N, Reinhart F, et al. Photobiomodulation-induced changes in a monkey model of Parkinson’s disease: changes in tyrosine hydroxylase cells and GDNF expression in the striatum. Experimental brain research. 2017;235(6):1861-74.
85. Peoples C, Spana S, Ashkan K, Benabid A-L, Stone J, Baker GE, et al. Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson’s disease. Parkinsonism & related disorders. 2012;18(5):469-76.
86. Shaw VE, Spana S, Ashkan K, Benabid AL, Stone J, Baker GE, et al. Neuroprotection of midbrain dopaminergic cells in MPTP‐treated mice after near‐infrared light treatment. Journal of Comparative Neurology. 2010;518(1):25-40.
87. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proceedings of the National Academy of Sciences. 2003;100(14):8514-9.
88. Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. The Journal of Immunology. 2005;175(7):4320-30.
89. O’Brien JA, Austin PJ. Effect of photobiomodulation in rescuing lipopolysaccharide-induced dopaminergic cell loss in the male sprague–dawley rat. Biomolecules. 2019;9(8):381.
90. El Massri N, Moro C, Torres N, Darlot F, Agay D, Chabrol C, et al. Near-infrared light treatment reduces astrogliosis in MPTP-treated monkeys. Experimental brain research. 2016;234(11):3225-32.
91. Reinhart F, El Massri N, Darlot F, Torres N, Johnstone DM, Chabrol C, et al. 810 nm near-infrared light offers neuroprotection and improves locomotor activity in MPTP-treated mice. Neuroscience Research. 2015;92:86-90.
92. Moro C, El Massri N, Torres N, Ratel D, De Jaeger X, Chabrol C, et al. Photobiomodulation inside the brain: a novel method of applying near-infrared light intracranially and its impact on dopaminergic cell survival in MPTP-treated mice. Journal of Neurosurgery. 2014;120(3):670-83.
93. Reinhart F, El Massri N, Chabrol C, Cretallaz C, Johnstone DM, Torres N, et al. Intracranial application of near-infrared light in a hemi-parkinsonian rat model: the impact on behavior and cell survival. Journal of Neurosurgery. 2016;124(6):1829-41.
94. Moro C, El Massri N, Darlot F, Torres N, Chabrol C, Agay D, et al. Effects of a higher dose of near-infrared light on clinical signs and neuroprotection in a monkey model of Parkinson's disease. Brain Research. 2016;1648:19-26.
95. Darlot F, Moro C, El Massri N, Chabrol C, Johnstone DM, Reinhart F, et al. Near‐infrared light is neuroprotective in a monkey model of P arkinson disease. Annals of neurology. 2016;79(1):59-75.
96. Ganeshan V, Skladnev NV, Kim JY, Mitrofanis J, Stone J, Johnstone DM. Pre-conditioning with remote photobiomodulation modulates the brain transcriptome and protects against MPTP insult in mice. Neuroscience. 2019;400:85-97.
97. Hong C-T, Hu C-J, Lin H-Y, Wu D. Effects of concomitant use of hydrogen water and photobiomodulation on Parkinson disease: A pilot study. Medicine. 2021;100(4).
- Abstract Viewed: 754 times
- PDF Downloaded: 591 times